Provided by Tiger Trade Technology Pte. Ltd.

ABBISKO-B

13.670
+0.1200.89%
Volume:1.50M
Turnover:20.15M
Market Cap:9.21B
PE:134.70
High:13.710
Open:13.550
Low:13.150
Close:13.550
52wk High:19.780
52wk Low:6.560
Shares:674.00M
HK Float Shares:674.00M
Volume Ratio:1.10
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.101
ROE:2.85%
ROA:0.78%
PB:4.18
PE(LYR):134.70
PS:13.12

Loading ...

ABBISKO-B (02256) Rises Over 4% in Late Trading as It Presents Long-Term Efficacy and Safety Data of Pimicotinib in Phase III MANEUVER Study

Stock News
·
Nov 20, 2025

Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast

Stock News
·
Nov 18, 2025

Abbisko Cayman Limited (2256) Reports Longer-Term Efficacy and Safety Data for Pimicotinib Phase III Study in TGCT

Bulletin Express
·
Nov 17, 2025

ABBISKO-B (02256): Subsidiary ABBISKO Presents Long-Term Efficacy and Safety Data of Pimicotinib Phase III MANEUVER Study at CTOS 2025 Annual Meeting

Stock News
·
Nov 17, 2025

Abbisko Cayman Reports Positive Long-Term Results for Pimicotinib in Phase III TGCT Study

Reuters
·
Nov 17, 2025

ABBISKO-B (02256) Completes First Patient Dosing in Phase II Clinical Trial of Oral Small-Molecule PD-L1 Inhibitor ABSK043 Combined with Golecerase for NSCLC Treatment

Stock News
·
Nov 03, 2025

Abbisko Therapeutics Doses First Patient in Phase II NSCLC Study

Reuters
·
Nov 03, 2025

Exploring the Depth and Breadth of ABBISKO-B's (02256) FIC/BIC Innovation Pipeline at R&D Day

Stock News
·
Oct 31, 2025

Guoyuan International Initiates Buy Rating on ABBISKO-B (02256) with Target Price of HK$22.06

Stock News
·
Oct 29, 2025

Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference

Stock News
·
Oct 27, 2025

Abbisko (2256) Presents Preclinical Findings on CDK4/2 Inhibitor and SMARCA2 PROTAC Degrader

Bulletin Express
·
Oct 27, 2025

ABBISKO-B (02256): ABK-CDK-1 and ABK-SM2-1 Exhibit Outstanding Preclinical Characteristics

Stock News
·
Oct 27, 2025

ABBISKO-B (02256) Showcases Long-term Efficacy and Safety Data of Pimicotinib in Phase III MANEUVER Study at ESMO 2025

Stock News
·
Oct 20, 2025

Abbisko Cayman Reports Positive Phase III Results for Pimicotinib in TGCT at ESMO 2025

Reuters
·
Oct 20, 2025